MARKET

CALA

CALA

Calithera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.75
-0.15
-2.17%
After Hours: 6.75 0 0.00% 16:00 01/24 EST
OPEN
6.94
PREV CLOSE
6.90
HIGH
6.94
LOW
6.50
VOLUME
526.32K
TURNOVER
--
52 WEEK HIGH
7.64
52 WEEK LOW
2.450
MARKET CAP
362.98M
P/E (TTM)
-3.2452
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CALA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CALA News

  • The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
  • Benzinga.01/15 13:22
  • Calithera Biosciences Expects to Use $75M to $85M of Cash in 2020
  • Benzinga.01/13 12:25
  • Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance
  • GlobeNewswire.01/13 12:07
  • Week 3 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
  • Seeking Alpha - Article.01/11 19:05

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About CALA

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.
More

Webull offers Calithera Biosciences Inc (CALA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.